Japan ALS Patient Group Petitions For Insurance Coverage For Edaravone
This article was originally published in PharmAsia News
Executive Summary
Japan's amyotrophic lateral sclerosis patient group petitioned to get insurance coverage for cerebral infarction drug Radicut (edaravone) injection for ALS treatment. Six patients and family members April 24 met Takao Watanabe, vice minister of the Ministry of Health, Labor and Welfare. The group complained that without insurance coverage, edaravone treatment costs ¥100,000 to ¥150,000 ($1,000 to $1,500) per month and many patients have to forgo the treatment. Watanabe said that clinical trials results have not proved efficacy of edaravone for ALS and the Ministry would consider other options to reduce patient costs. (Click here for more - Japanese language
|
Japan's amyotrophic lateral sclerosis patient group petitioned to get insurance coverage for cerebral infarction drug Radicut (edaravone) injection for ALS treatment. Six patients and family members April 24 met Takao Watanabe, vice minister of the Ministry of Health, Labor and Welfare. The group complained that without insurance coverage, edaravone treatment costs ¥100,000 to ¥150,000 ($1,000 to $1,500) per month and many patients have to forgo the treatment. Watanabe said that clinical trials results have not proved efficacy of edaravone for ALS and the Ministry would consider other options to reduce patient costs. (Click here for more - Japanese language) "ALS Patients Petition MHLW For Insurance Coverage For Edaravone" - Kyodo Press News (4/24/09) |